Pregnancy Exposure Registries for Assessing Antimalarial Drug Safety in Pregnancy in Malaria-Endemic Countries
Year: 2008
Type: review
Abstract: Because pregnant women are routinely excluded from prelicensure clinical trials for fear of harming the mother or the developing foetus [1], most drugs are marketed with limited information on their safety during pregnancy and therefore are not recommended for use by pregnant women. Yet drugs are widely used by pregnant women, and medication often cannot be avoided in chronic diseases such as epilepsy and HIV or other acute illness that harm the mother and the unborn child if left untreated. Passive mechanisms of spontaneous reporting of adverse drug effects are inadequate for detecting druginduced foetal risks or lack of such risks [2]. The US Food and Drug Administration and the European Medicine Agency recommend active surveillance, such as the use of pregnancy exposure registries (PERs), for products that are likely to be used during pregnancy or by women of childbearing age (WOCBAs), particularly if there have been case reports of adverse pregnancy outcome following exposure, if drugs in the same pharmacological class are known to pose risk during pregnancy, or if pre-clinical animal data suggest potential teratogenic risk [3,4]. In industrialised countries, this information can be derived from medical records and automated databases, including medical or pharmacy insurance claims. Such approaches are challenging in developing countries where resources for routine pharmacovigilance are rare and automated data sources generally do not exist [5–8]. Thus, nearly all developing countries rely on The Health in Action section is a forum for individuals or organizations to highlight their innovative approaches to a particular health problem.
Source: PLoS Medicine
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,460
OpenAlex ID: W2059320856
